Intellectus Partners, LLC Gilead Sciences, Inc. Transaction History

Intellectus Partners, LLC

$383 Million
Q3 2024

A detailed history of Intellectus Partners, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Intellectus Partners, LLC holds 21,429 shares of GILD stock, worth $2.01 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares

21,429

Previous 40,759 47.43%

Holding current value

$2.01 Million

Previous $2.8 Million 35.77%

% of portfolio

0.47%

Previous 0.77%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$66.59 - $83.99 $1.29 Million - $1.62 Million	-19,330 Reduced 47.43%	21,429 $1.8 Million
Q2 2024 Jul 18, 2024	BUY	$63.15 - $72.88 $234,981 - $271,186	3,721 Added 10.05%	40,759 $2.8 Million
Q1 2024 May 03, 2024	BUY	$71.58 - $87.29 $503,064 - $613,474	7,028 Added 23.42%	37,038 $2.71 Million
Q4 2023 Feb 05, 2024	SELL	$73.27 - $83.09 $335,210 - $380,136	-4,575 Reduced 13.23%	30,010 $2.43 Million
Q3 2023 Oct 25, 2023	SELL	$73.94 - $80.67 $206,588 - $225,391	-2,794 Reduced 7.47%	34,585 $2.59 Million
Q2 2023 Jul 31, 2023	SELL	$76.01 - $86.7 $116,523 - $132,911	-1,533 Reduced 3.94%	37,379 $2.88 Million
Q1 2023 May 04, 2023	SELL	$77.31 - $88.08 $2,551 - $2,906	-33 Reduced 0.08%	38,912 $3.23 Million
Q4 2022 Feb 02, 2023	SELL	$62.32 - $89.47 $748,837 - $1.08 Million	-12,016 Reduced 23.58%	38,945 $3.34 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $2,202 - $2,516	-37 Reduced 0.07%	50,961 $3.14 Million
Q2 2022 Aug 12, 2022	SELL	$57.72 - $65.01 $23,838 - $26,849	-413 Reduced 0.8%	50,998 $3.15 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $10,715 - $13,427	185 Added 0.36%	51,411 $3.06 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $11,029 - $12,518	-170 Reduced 0.33%	51,226 $3.72 Million
Q3 2021 Nov 16, 2021	SELL	$67.69 - $73.03 $70,939 - $76,535	-1,048 Reduced 2.0%	51,396 $3.59 Million
Q2 2021 Aug 13, 2021	BUY	$63.47 - $69.35 $6,727 - $7,351	106 Added 0.2%	52,444 $3.61 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $1.07 Million - $1.23 Million	17,902 Added 51.99%	52,338 $3.38 Million
Q4 2020 Feb 18, 2021	BUY	$56.65 - $64.55 $1.91 Million - $2.18 Million	33,761 Added 5001.63%	34,436 $2.01 Million
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $2.88 Million - $3.28 Million	-50,795 Reduced 98.69%	675 $2.01 Million
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $89,424 - $112,435	1,440 Added 2.88%	51,470 $3.25 Million
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $32,191 - $37,380	-445 Reduced 0.88%	50,030 $3.85 Million
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $531,666 - $680,987	-8,489 Reduced 14.4%	50,475 $3.77 Million
Q4 2019 Jan 24, 2020	SELL	$61.62 - $67.78 $97,297 - $107,024	-1,579 Reduced 2.61%	58,964 $3.83 Million
Q3 2019 Oct 11, 2019	SELL	$62.51 - $69.0 $7,188 - $7,935	-115 Reduced 0.19%	60,543 $3.84 Million
Q2 2019 Aug 08, 2019	BUY	$61.87 - $69.38 $41,576 - $46,623	672 Added 1.12%	60,658 $4.1 Million
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $984,347 - $1.1 Million	-15,742 Reduced 20.79%	59,986 $3.9 Million
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $3.52 Million - $4.59 Million	58,080 Added 329.1%	75,728 $4.74 Million
Q3 2018 Nov 15, 2018	SELL	$71.28 - $78.92 $93,376 - $103,385	-1,310 Reduced 6.91%	17,648 $1.36 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $47,751 - $55,700	736 Added 4.04%	18,958 $1.34 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $163,890 - $199,800	2,250 Added 14.09%	18,222 $1.37 Million
Q4 2017 Feb 13, 2018	SELL	$71.15 - $83.52 $61,615 - $72,328	-866 Reduced 5.14%	15,972 $1.14 Million
Q3 2017 Nov 14, 2017	SELL	$72.11 - $85.47 $261,038 - $309,401	-3,620 Reduced 17.69%	16,838 $1.36 Million
Q2 2017 Aug 15, 2017	BUY	N/A	20,458	20,458 $1.45 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Intellectus Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Intellectus Partners, LLC with notifications on news.

Account

Intellectus Partners, LLC Gilead Sciences, Inc. Transaction History